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Modulation of Potassium Channels by Antiarrhythmic and Antihypertensive Drugs
Michael C. Sanguinetti
Agents that modulate cardiac and smooth muscle K + channels have stimulated considerable interest in recent years because of their therapeutic potential in a number of cardiovascular diseases. Foremost among these drugs are the so-called Class III antiarrhythmic agents, which act by prolonging cardiac action potentials, and K + channel openers, which hyperpolarize and thereby relax smooth muscle cells. Many of the newly developed Class III antiarrhythmic agents probably act by specific block of one subtype of delayed rectifier K + current, I Kr , whereas other agents block more than one type of cardiac K + current. Much controversy exists over the specific type of K + channel (or channels) in smooth muscle that are activated by the K + channel openers. Both groups of K + channel modulators have great therapeutic promise, but the Class III antiarrhythmic agents may suffer from a side-effect that is directly linked to their specific mechanism of action. channel blockers that occurred during the late 1970s and throughout the 1980s, there is now a tremendous interest in development of drugs that specifically modulate K + channels. The development of new voltage clamp techniques during the past decade has enabled the recording of whole cell currents from single cells and single channel currents from isolated membrane patches. 1 These techniques have allowed the cellular mechanisms of these novel agents to be explored more rapidly and by more laboratories than was the case for the Ca 2+ channel blocking drugs. The widespread availability of this method has also resulted in greater controversy regarding the mechanisms of action of the new K + channel modulators. This is especially true for the potassium channel openers (PCOs) (also known as K + channel agonists or K + channel activators). The cellular mechanism of action of such agents as cromakalim, nicorandil, pinacidil, and RP 49356 in cardiac muscle is generally agreed to be activation of the ATP-sensitive K + channel (K ATP ). However, a consensus regarding the mechanism of action of these same drugs in smooth muscle has yet to be achieved. A similar, if only minor controversy also exists with regard to the specific K + channels that are blocked by the newly developed and very potent class III antiarrhythmic (C3A) agents, exemplified by E-4031 and UK-68,798.
This brief tutorial reviews the proposed cellular mechanisms of action of two classes of novel K + channel modulators that have the most promising therapeutic potential in cardiovascular medicine, the C3A agents and PCOs. Class III Antiarrhythmic Agents Cardiac cells are characterized by the presence of a dizzying array of different K + channel subtypes. Inward rectifier K + channels (I K1 ) are primarily responsible for maintaining the resting potential near the equilibrium potential for K + (E K ) and for terminal repolarization of the action potential (from about -20 to -90 mV). I K1 channels open (activate) almost instantly in response to a change in membrane potential and allow inward K + current to pass more easily than outward K + current ("inward rectification"). The major role of the numerous other cardiac K + currents is to initiate or at least participate in repolarization of the action potential. The major currents responsible for repolarization of heart cells are the transient outward (I to ) and delayed rectifier (I K ) K + currents. I lo channels are so named because they are open only transiently, that is, these channels close (inactivate) soon after opening in response to a positive change in membrane potential (depolarization) and thus only contribute to the initial phase of repolarization. Delayed rectifier channels are so named because they open in response to a depolarization only after a distinct delay, and a plot of current through these channels versus membrane potential (current-voltage plot) is not linear (the current exhibits rectification). As discussed below, there are at least two types of I K channels (IKJ and I Kr ) in ventricular and atrial cells. 23 In addition, cardiac cells have channels that are either inhibited by intracellular ATP (K-ATP channels) or activated by intracellular sodium or by external acetylcholine (K AC h channels). Not all channel types are found in a given cell type. For example, guinea pig ventricular cells have little or no I to , and K ACh channels are restricted to atrial cells. The hallmark of cardiac action potentials, a long plateau phase, results from either a very slow rate of activation (e.g., IRS) or intense inward rectification (e.g., Iia, I Kr ) of repolarizing K + currents. Antiarrhythmic Effects of C3A Drugs: Mechanism of Action Antiarrhythmic effects of the C3A agents result from prolongation of cardiac action potentials ( Figure 1A ) and thus refractory period of the myocardium. Lengthening of refractory period by these drugs is associated with a decrease in the incidence of reentrant ventricular arrhythmias. 5 Reentrant arrhythmias are believed to be the major cause of ventricular fibrillation, the lethal rhythm disorder associated with sudden cardiac death. 6 In addition to prolonging action potential duration, most C3A drugs also enhance contractility, decrease defibrillation threshold, and slightly slow heart rate.
The prototypical C3A drugs are amiodarone, clofilium, and sotalol. Although amiodarone and sotalol have been studied more than any other C3A agents, none are "pure" in that they also have significant Class I activity (block Na + current: amiodarone and clofilium), Class II activity (block 0-adrenergic receptors: sotalol), or Class IV activity (block Ca 2+ current: amiodarone). Amiodarone is usually administered to patients for extended periods before antiarrhythmic effects are noted, and probably acts by blocking a variety of cardiac channels, 7 but a voltage-dependent block of I K may be responsible for its acute C3A activity. 8 Clofilium has potent (EC5o=13 nM) C3A activity in canine cardiac Purkinje fibers but has no effect on atrial muscle at 100 nM. 9 Even higher concentrations (more than 10 (iM) are required to prolong action potential duration of guinea pig ventricular cells. Clofilium blocks I K in isolated guinea pig ventricular myocytes with an IQo of approximately 50 /xM 10 and blocks I,,, in rat myocytes in a frequency-dependent manner with an IC*, less than 1 uM.
n The basis of its potent action on cardiac Purkinje cells has yet to be adequately explained but could possibly result from a more potent block of I K in these cells or from high affinity block of a large conductance, Ca 2+ -activated K + channel present in these cells, 12 but not in other cardiac cell types.
Sotalol is a 0-adrenergic receptor blocker that also has C3A activity in humans.
13 The ( -) enantiomer is more potent as a j3-adrenergic receptor blocker than the (+) enantiomer, but both are equieffective as C3A drugs. Contrary to widely held beliefs, (+)-sotalol has significant /J-adrenergic receptor blocking activity ( P K D = 5 . 0 , determined by inhibition of 12i I-pindolol binding) relative to its potency as a C3A in isolated guinea pig hearts: pECso=4.9.
14 Carmeliet 15 was the first to demonstrate the cellular mechanism of action of racemic sotalol and both its enantiomers in isolated rabbit Purkinje fibers. IK, measured as deactivating tail currents, was blocked about 50% by 10 /iM sotalol. This concentration had no significant effect on I,o, I K i, or sodium current in this preparation. Greater than 90% block of I K was observed at 100 uM. In contrast, Berger et al 16 reported that (+)-sotalol or (±)-sotalol blocked I,,, and IKI by 23% and 7%, respectively, at 10 fiM but had no effect on I K at 100 /xM in isolated sheep cardiac Purkinje fibers. I K was decreased by only 16% at 1 mM in the sheep fibers. The species-dependent effect of sotalol on I K is well correlated with its ability to prolong action potential duration. Sotalol (10 fiM) lengthened action potential duration by 41% in rabbit Purkinje fibers 15 but only by 5% in sheep Purkinje fibers. 16 This raises the obvious possibility that I K represents the activation of different channel types in the two species. Guinea pig ventricular muscle is similar to sheep Purkinje fibers with respect to its sensitivity to sotalol. However, as discussed below, I K of guinea pig myocytes actually represents the sum of two distinct outward K + currents. The first voltage clamp analysis of I K in cardiac tissue was performed by Noble and Tsien. 17 They proposed that I K in sheep Purkinje fibers was the composite of two distinct currents, called I xl and I l2 . These currents were separable on the basis of kinetics, reversal potential, and degree of rectification. Subsequent studies concluded that quantitative analysis of I K in such a multicellular preparation was hampered by accumulation of K + in intracellular clefts, 18 and that the multiexponential onset of I K activation and subsequent deactivation could be adequately described in guinea pig myocytes assuming either n 2 Hodgkin-Huxley-like activation ki- sotalol at 100 uM had no measurable effect on outward I K in guinea pig ventricular myocytes when measured during long pulses at very depolarized potentials.
2 However, sotalol did block a small component of I K when measured at test potentials negative to +50 mV. The sotalol-sensitive current was maximum at 0 mV and reached steady state during relatively short depolarizing pulses (less than 200 msec). This result indicated that either sotalol exerts a voltage-dependent but very limited block of I K or that I K was composed of at least two currents, one of which was sensitive to block by sotalol. The latter possibility was shown to be correct in a more detailed study of the mechanism of action of sotalol and another structurally related C3A agent, E-4031. 2 Both sotalol and E-4031 are methanesulfonanilides, but E-4031 is about 100-fold more potent than sotalol as a C3A drug. 21 - 23 The E-4031-sensitive component of I K activates very rapidly relative to the E-4031-insensitive component. In addition, the drug-sensitive component exhibits marked inward rectification (current reaches a maximum near 0 mV, then declines at more positive voltages, Figure 2 ). The current blocked by sotalol and E-4031 has been named " 1^" to signify its rapid activation and rectification properties. The drug-insensitive current named "1^," slowly activates and is characterized by only slight rectification. Complete activation of IK, requires many seconds and reaches a level that is about 10-fold greater than I Kn as measured by deactivating tail currents. IK, activates fast enough to reach steady state during the time course of a normal action potential, whereas the onset of I K , is so slow that it only reaches a small fraction of its steady-state activation during the same time period. In guinea pig ventricular cells I K , and IR, activate to equivalent magnitudes during a 225-msec pulse to 0 mV.
-
24 Thus, in the time frame of a cardiac action potential both currents are important in terminating repolarization.
I K of rabbit cardiac Purkinje cells activates relatively fast and exhibits marked inward rectification. 25 It seems quite plausible that I K of rabbit Purkinje cells is equivalent to IKT of guinea pig myocytes, thus explaining the ability of sotalol to completely block I K in whole Purkinje fibers.
14 IK, and IK, are also present in guinea pig atrial cells. 3 ' 26 In these cells, Horie et al 27 recorded two distinct types of single channel currents that may correspond to I Kr and IK, of whole cell currents. In insideout patch recordings the conductance of the two channels were 3 and 10 picosiemens (pS) when measured in symmetrical K + (150 mM) conditions. The 3-pS channel deactivated more slowly than the 10-pS channel, suggesting that the two channels represent the unit activity underlying IK, and I Kn respectively. In rabbit nodal cells, I K is almost indistinguishable from 1^ recorded from guinea pig myocytes.
-28
The conductance of single I K channels in these nodal cells was 11 pS, in good agreement with the similar channel (I Kr ?) recorded from guinea pig atrial myocytes. 27 Single channel currents corresponding to IK, were not resolvable in patches of guinea pig ventricular cells, suggesting that the channels have an extremely low conductance (less than 1 pS in physiological K + gradient) and are present at high density in cardiac sarcolemmal membrane. 29 Two types of I K have also been described in embryonic chick atrial cells, 30 but the effect of C3A drugs has yet to be evaluated in this preparation.
A K + channel with very slow activation kinetics was recently isolated by expression cloning from rat kidney. 31 Complementary DNAs (cDNAs) encoding this channel protein ( " W ) have since been cloned and expressed from neonatal rat heart 32 and human heart 33 and may be the protein that forms I Kl channels, presumably as homooligomers. The l A protein is unlike any other K + channel protein both in primary sequence and its unusually small size, only 130 amino acids.
-32
Not All C3A Agents Are Specific I Kr Blockers Several other newly developed C3A agents that are structurally related to sotalol and E-4031 may also act by selectively blocking I Kr -Examples include UK-68,798,"-34 UK-66,914,« anc j sematilide. 36 The selective action of these drugs is true only with respect to other cardiac channels. UK-68,798 was also reported to block a Ca 2+ -activated K + channel recorded from CA1 hippocampal neurons. 37 Several drugs have C3A properties in addition to other activities. For example, OPC-8490 is an inotropic agent and quinidine is a Class I antiar- 40 This suggests that the clinically relevant C3A action of quinidine may be block of IKJ and not IR,. Pirmenol, a pyridine methanol derivative, blocks both I K and I N , in rabbit Purkinje fibers, similar to quinidine, and is therefore best classified as a class la antiarrhythmic agent. 41 Tedisamil is a diazobicyclic C3A and bradycardic agent that blocks I to and I K in rodent cardiac cells and mouse astrocytes. 42 Tedisamil has no effect on I H or Ic. at concentrations that cause a voltage-independent, open channel block of I,o and I K with apparent K D 's of 2.5 and 4.5 /xM, respectively. Tedisamil did not alter the steady-state voltage dependence of 1^ inactivation nor the usedependent decrease in I w magnitude. 42 This compound is a C3A agent in rat cardiac muscle due to its block of l u but acts by blocking I K in guinea pig ventricular myocytes that have little or no I^. The methanesulfonanilide UK-68,798 has no effect in adult rat heart, consistent with the apparent absence of I K in this species. 4 RP 58866 is a benzopyran derivative that was reported to decrease outward I K i but had little effect on inward I K1 . At concentrations (0.1-30 JAM) required for C3A activity, RP 58866 had no effect on IK, IRATP, or Ic,. 43 Although several agents with C3A activity block IKI in addition to other actions (e.g., quinidine), RP 58866 is the first pure C3A drug that apparently acts by selective block of IRI-The mechanisms of action of C3A drugs that act at least in part by blocking one or more types of cardiac K + channels are summarized in Table 1 .
Rate-Dependence and Proarrhythmic Effects of C3A Drugs
An unfortunate side effect of almost all C3A agents is their propensity toward inducing a distinct ventricular tachyarrhythmia, torsades de pointes. 44 Torsades de pointes as defined here is associated with a long QT interval and is characterized by a sinusoidal-like pattern of the surface electrocardiogram. It is widely believed that the cellular basis of this arrhythmia is the development of early after depolarizations (EADs) ( Figure IB) resulting from incomplete repolarization of the cardiac action potential. 44 EADs have been recorded from isolated cardiac tissue treated with almost all C3A drugs and were recently recorded from patients with torsades de pointes. 45 An in vivo model of torsades de pointes revealed that the doses of cesium, sematilide, clofilium, LY 97119, amperozide, or UK-68,798 required to prolong the QT interval in anesthetized rabbits was extremely well correlated with the dose that produced ventricular tachycardia. 46 Theoretically, induction of torsades de pointes is not an unavoidable consequence of C3A drug therapy. This arrhythmia is usually preceded by a long diastolic interval immediately before initiation of the tachyarrhythmia.
44 C3A drugs are all more effective at prolonging action potential duration at slow, relative to fast, heart rates.
-
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- 4748 Therefore, C3A drugs are more likely to induce EADs, and thereby torsades de pointes, at slow heart rates or after an unusually long diastolic pause. As discussed by Hondeghem and Snyders, 47 an agent that prolonged action potential duration preferentially at fast heart rates with little effect at slow rates would have less propensity toward precipitation of torsades de pointes. Unfortunately, a C3A agent with such a profile does not exist. The newly developed methanesulfonanilide C3A drugs (e.g., E-4031 and UK-68,798) apparently do not induce torsades de pointes in dogs, the species most used for drug efficacy studies. cardiac action potential. In rabbit cardiac myocytes there is little or no lie-like current, 15 whereas dog and guinea pig myocytes have a relatively large I K , in addition to IK,. 2 Virtually nothing is known about the types of K + channels that control repolarization in human ventricular cells. However, C3A drugs can also induce torsades de pointes in humans, especially in patients who are hypokalemic or have unusually slow heart rates. 44 Sudden cardiac death resulting from ventricular fibrillation can also be caused by a rare inherited disease called long QT syndrome. The exact nature of the inherited defect is unknown, but genetic analysis suggests a highly probable link with the Harvey-ras-1 gene, which codes for a GTP-binding protein that may in turn modulate K + channel activity.
49
The mechanism of rate-dependent lengthening of action potentials by C3A drugs is not well understood. It has been proposed that agents such as E-4031 preferentially block open I K channels 48 ; however, this mode of block would be expected to result in the opposite effect: greater lengthening at fast rates. In guinea pig myocytes, the magnitude of IK, was not altered by applying depolarizing pulses at frequencies of either 0.5 or 3 Hz (NK Jurkiewicz and MC Sanguinetti, unpublished observations). Although UK-68,798 (1 fiM) completely blocked IK, in these cells following trains of pulses delivered at either frequency, action potential lengthening is much greater at the slower pacing frequency. The rale-dependent prolongation of action potentials by C3A drugs may reflect the greater contribution of IK, and IKI to total outward, repolarizing current that occurs at higher pacing frequencies in these cells. 50 The increase in I K1 (and perhaps increased rate of Ic. inactivation) more than offsets the block of IK, at higher pacing rates, limiting the effectiveness of these drugs to prolong action potential duration and refractory period.
The ability of C3A drugs to prolong action potential duration is also influenced by the presence of 0-adrenergic receptor agonists. Lengthening of refractory period by E-4031 in isolated papillary muscles was nearly abolished if muscles were pretreated with isoproterenol. 24 Isoproterenol increased the conductance of I Kl , I c and a chloride current but had no effect on IK,. 24 The augmentation of these other currents by isoproterenol has the same functional effect as rapid heart rates on the ability of C3A agents such as E-4031 to prolong action potentials. Thus, C3A drugs would be expected to have decreased efficacy in the presence of high sympathetic tone, high heart rates, or both.
Potassium Channel Openers
Several PCOs are currently in clinical trials for treatment of hypertension and may be useful as cardioprotectants. 51 " 54 PCOs may represent potential therapies for other disorders such as angina pectoris, asthma, irritable bladder syndrome, 55 and perhaps even epilepsy. 56 The PCOs represent a very diverse group of chemical structures that most likely do not share a single common mechanism. Seven distinct classes of PCOs are recognized 57 : the benzopyrans (e.g., cromakalim and EMD 52692), cyanoguanidines (e.g., pinacidil), nicotinomides (e.g., nicorandil), thioformamides (e.g., RP 49356), pyrimidine oxides (e.g., minoxidil), benzothiadiazines (e.g., diazoxide), and a dihydropyridine (niguldipine). The clinical use of these drugs may be limited by their lack of vascular bed selectivity. The following discussion is primarily restricted to the proposed mechanisms of action of the PCOs in cardiac and smooth muscle cells. The reader is referred to several excellent recent reviews for more complete discussions of the general pharmacology, 
Mechanism of Action in Cardiac Cells
The most likely clinical use of PCOs will be as smooth muscle relaxants; however, the cellular mechanisms of action of diazoxide and cromakalim were first determined in ^-pancreatic cells 60 and cardiac cells.
61
- 62 In all studies of cardiac ceils, the PCOs have been demonstrated to be specific activators of K ATP channels. 61 -68 Cardiac K ATP channels have a unit conductance of 25 and 80 pS in the presence of 5 or 140 mM intracellular K + , respectively, and are inhibited by intracellular ATP (ATP,) with a K, of 17-100 nM, being dependent on many factors such as the ATP,/ADP, ratio, pH, and intracellular Mg 2 * concentration. 69 " 73 The open probability (P o ) of K ATP channels in cardiac cells under normal conditions is extremely low, such that exposure of cells to antidiabetic sulfonylureas (e.g., glibenclamide and tolbutamide) that block these channels have no measurable effect on action potentials or net membrane currents. 61 -63 - 74 The P o of K ATP channels is increased when intracellular ATP concentration ([ATP],) is lowered, either artificially in excised patches or in whole cells exposed to hypoxic conditions or metabolic inhibitors. 69 - 72 However, the physiological importance of K ATP channels during ischemia, hypoxia, or metabolic poisoning has long been in doubt, since a profound shortening of cardiac action potentials can be measured at times when [ATP], is only slightly decreased. Recent studies have shed light on the apparent discrepancy between the measured decrease in [ATP], (a drop from 5.4 to 4.3 mM) 75 and the K, (17-100 /xM) 69 for block of the channels by ATP. It has been estimated that opening of less than 1% of the total number of K ATP channels activated by either a PCO (SR 44866) 76 or complete metabolic blockade 77 is required to shorten action potential duration by 50%. Less than 10% of the K ATP current that could be activated by SR 44866 was sufficient to make an isolated guinea pig myocyte electrically inexcitable. 78 Thus, very small increases in the P o of K ATP channels by PCOs, even in the presence of near normal [ATP],, will result in considerable shortening of cardiac action potentials (Figure 3 ). The effect of PCOs on K ATP activity depends on [ATP],; less of a stimulatory effect occurs at higher internal ATP levels. 64 -" 79 ' 80 In inside-out patches of guinea pig myocytes, 30 fiM RP 49356 shifted the concentration-response for ATP closure of K ATP channels by one order of magnitude. 79 PCOs have either arrhythmogenic 81 -83 or antiarrhythmic 84 properties, depending on the experimental model in which they are examined. Glibenclamide prevents ventricular fibrillation in the ischemic rat heart, 81 -83 but not in the dog. 85 Block of K ATP channels during ischemia may even have deleterious effects, exacerbating myocardial stunning during reperfusion. 86 Such an undesirable effect is not unexpected considering the suggested physiological role of cardiac K ATP channels. Noma 87 proposed that during ischemia, activation of these channels accompanied by action potential shortening might act to protect the contractile cells from intracellular Ca 2+ overload. A high concentration of RP 49356 (100 uM) had no effect on contractile activity of isolated rat myocytes when cells were bathed in a solution containing 10 mM glucose but had profound negative inotropic effects if glucose was replaced with 2-deoxyglucose. 68 This may explain why many of the PCOs have cardioprotective effects in ischemia models at doses that do not have measurable effects on coronary flow or cardiac function under control conditions. 51 -55 - 68 The proposed mechanisms of action for the various reported effects of the PCOs on cardiac and smooth muscle are summarized in Figure 4 .
Mechanism of Action in Smooth Muscle Cells
The molecular target of PCOs in smooth muscle cells is a matter of considerable controversy. Pharmacological evidence and ^Rb* efflux studies support the idea that all PCOs relax smooth muscle by increasing K + efflux, causing hyperpolarization that, in turn, limits the entry of extracellular Ca 2+ required for sustained contraction ( Figure 5 ). The general pharmacology of PCOs is reviewed elsewhere.
54 " 59 However, there is not a consensus regarding the specific channel type (or types) that are opened by these drugs. Glibenclamide is a specific blocker of K ATP current in ^-pancreatic and cardiac cells 61 -63 ' 74 and is therefore often used as a pharmacological probe to determine if a given PCO acts by activation of K ATP channels. The vasorelaxant action of CTomakalim, minoxidil sulfate, and diazoxide in rat portal venous strips was inhibited by glibenclamide (0.1-30 uM) but not by toxins that block Ca 2+ -activated K + channels, apamin, or charybdotoxin. 89 The decrease in coronary perfusion pressure caused by cromakalim, hypoxia, or ischemia in isolated guinea pig hearts could be prevented by pretreatment with glibenclamide. 90 The increase in 42 K + efflux induced by cromakalim or ATP ( ; depletion in rabbit mesenteric arteries was greatest in Ca 2+ -free solutions and antagonized by glibenclamide. 91 Together these findings provide strong pharmacological evidence that PCOs open K ATP channels but not Ca 2+ -activated K + channels. The use of glibenclamide as a specific probe may not be valid in smooth muscle preparations, since this agent also blocks the large conductance, Ca 2+ -activated K + channel (BK a ) activated by PCOs. Voltage clamp experiments performed in the last 3 years have only added to the apparent complexity regarding the type of channel (or channels) that are activated by the PCOs. Cromakalim was demonstrated to activate a large conductance (135 pS in 60 K + (V120 K + i), Ca 2+ -insensitive, ATP r inhibited K + channel in rat mesenteric artery cells. 93 The conductance of these channels is about twofold to threefold greater than that of K ATP channels of cardiac or pancreatic B-cells but almost identical to B K a channels under similar ionic conditions. However, unlike B K a channels, the activity of these channels was recorded in a Ca 2+ -free solution (5 EGTA in pipette), unaffected by charybdotoxin (100 nM), and blocked by glibenclamide. 93 In the same preparation, BK & channels were shown to be unaffected by 1 mM ATP, 1 fiM glyburide, or 10 /JM cromakalim. In contrast, BK Q channels that are regulated by ATP f and activated by PCOs have been recorded from other smooth muscle cell types 94 -96 and from aortic microsomes incorporated into planar lipid bilayers. 97 Cromakalim at 50 nM increased P o of B K a channels incorporated into bilayers from 0.1 to 0.16 (at -40 mV, pCa=6), equivalent to a -15 mV shift in the P o -voltage curve. 97 In porcine coronary artery cells a channel similar to B K a with respect to conductance and Ca 2+ sensitivity but inhibited by ATP, (^=0.3-0.5 mM at 0 mV, pCa=6) was given the name KA^C,. 9 4 K A TP,C» channels were also recorded from rabbit aortic and tracheal smooth muscle cells. 9596 Cromakalim reversed the inhibitory effects of ATP, (increased P o ) on these channels. 95 - 97 A possible role for other Ca 2+ -activated K + channels in the action of nicorandil has also been suggested. The outward K + current induced by nicorandil in isolated rat portal vein cells was suppressed in nominally Ca 2+ -free solutions. 98 In these cells, nicorandil increased P o of a 10 pS Ca 2+ -activated K + channel but not the 132 pS B K a channel. Another proposed target for cromakalim is the delayed rectifier K + channel in rabbit portal vein. 99 In the same preparation, pinacidil inhibits an oscillatory outward K + current that is activated by intracellular Ca 2+ released from the sarcoplasmic reticulum. 100 Block of this K + current by pinacidil would presumably increase the excitability of portal vein cells if not offset by greater activation of other K + channel types. Interestingly, glibenclamide prevented the ability of pinacidil to inhibit the oscillatory K + current.
100
Mechanism of Action in Other Cell Types In insulin-secreting cells (RINm5F cells), cromakalim, pinacidil, RP 49356, nicorandil, and diazoxide activate K ATP channels but only at concentrations greater than 100 /iM. 101 -102 When ATP facing the inside of the membrane patch was replaced with ATP-yS, diazoxide and cromakalim no longer were capable of activating K A TP channels, leading to the proposal that these channel activators act via protein phosphorylation. 101 In mouse skeletal muscle the activation of K ATP channels by cromakalim and pinacidil but not RP 49356 required the presence of ATP on the internal side of the membrane patch. 103 These PCOs had no effect on BKQ, channels in this preparation. In membrane blebs of human skeletal muscle, several PCOs (EMD 52692, RP 49356, and cromakalim) were reported to activate both an ATP-sensitive and an ATP-insensitive K + channel. 104 Neither channel type was Ca 2+ ,-dependent, since the recordings were obtained in a Ca 2+ -free medium. Activation by PCOs of either channel type was reversed by glibenclamide. This result once again emphasizes the uncertainty in using this blocker to prove a role for K ATP channels in the action of specific PCOs. 
Summary
